Eyepoint Historical Income Statement

EYPT Stock

USD 9.23 0.28 3.13%

Historical analysis of Eyepoint Pharmaceuticals income statement accounts such as Total Revenue of 48.3 M or Gross Profit of 43.5 M can show how well Eyepoint Pharmaceuticals performed in making a profits. Evaluating Eyepoint Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Eyepoint Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Eyepoint Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eyepoint Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.

About Eyepoint Income Statement Analysis

Eyepoint Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Eyepoint Pharmaceuticals shareholders. The income statement also shows Eyepoint investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Eyepoint Pharmaceuticals Income Statement Chart

At this time, Eyepoint Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Selling And Marketing Expenses is likely to gain to about 17 M in 2024, despite the fact that EBIT is likely to grow to (66 M).

Total Revenue Other Operating Expenses Research Development Total Operating Expenses Tax Provision

Total Revenue

Total revenue comprises all receipts Eyepoint Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Eyepoint Pharmaceuticals. It is also known as Eyepoint Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Eyepoint Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eyepoint Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.At this time, Eyepoint Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Selling And Marketing Expenses is likely to gain to about 17 M in 2024, despite the fact that EBIT is likely to grow to (66 M).

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	2.8M	2.4M	464K	440.8K
Interest Income	292K	2.1M	6.9M	3.8M

Reconciled Depreciation Interest Income

Eyepoint Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Cost Of Revenue	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.51	-0.01	-0.16	0.04	-0.13	-0.16	-0.22	-0.12	0.03	-0.27	-0.53	-0.31	0.1	-0.05	-0.18	0.41	-0.26	0.03	0.17	-0.04	-0.7	0.14	0.72
Interest Expense	0.51		0.55	0.5	0.56	-0.53	-0.53	0.22	-0.51	0.54	-0.56	-0.17	-0.58	0.45	0.44	-0.38	0.92	-0.44	0.35	0.09	0.48	-0.62	-0.09	0.79
Total Revenue	-0.01	0.55		0.96	0.93	-0.8	-0.78	0.86	-0.79	0.93	-0.72	0.28	-0.71	0.49	0.92	-0.42	0.73	-0.62	0.37	0.23	0.67	0.18	0.02	0.22
Gross Profit	-0.16	0.5	0.96		0.86	-0.71	-0.69	0.8	-0.7	0.86	-0.59	0.46	-0.59	0.58	0.85	-0.43	0.68	-0.47	0.42	0.16	0.61	0.26	-0.17	0.09
Other Operating Expenses	0.04	0.56	0.93	0.86		-0.96	-0.94	0.93	-0.94	1.0	-0.89	0.2	-0.88	0.46	0.99	-0.46	0.78	-0.74	0.35	0.19	0.81	0.19	0.15	0.29
Operating Income	-0.13	-0.53	-0.8	-0.71	-0.96		0.95	-0.88	0.95	-0.96	0.96	-0.06	0.94	-0.43	-0.94	0.47	-0.75	0.76	-0.26	-0.17	-0.8	-0.15	-0.21	-0.33
Ebit	-0.16	-0.53	-0.78	-0.69	-0.94	0.95		-0.84	1.0	-0.93	0.95	-0.12	0.95	-0.48	-0.91	0.38	-0.76	0.82	-0.39	-0.15	-0.78	-0.08	-0.22	-0.4
Research Development	-0.22	0.22	0.86	0.8	0.93	-0.88	-0.84		-0.85	0.94	-0.78	0.29	-0.74	0.28	0.97	-0.36	0.48	-0.68	0.28	0.15	0.78	0.5	0.25	-0.03
Ebitda	-0.12	-0.51	-0.79	-0.7	-0.94	0.95	1.0	-0.85		-0.94	0.95	-0.14	0.95	-0.48	-0.91	0.38	-0.74	0.81	-0.39	-0.14	-0.78	-0.11	-0.21	-0.38
Total Operating Expenses	0.03	0.54	0.93	0.86	1.0	-0.96	-0.93	0.94	-0.94		-0.89	0.2	-0.87	0.44	0.99	-0.46	0.76	-0.74	0.35	0.19	0.81	0.21	0.16	0.26
Income Before Tax	-0.27	-0.56	-0.72	-0.59	-0.89	0.96	0.95	-0.78	0.95	-0.89		0.15	0.99	-0.35	-0.86	0.35	-0.75	0.86	-0.31	-0.16	-0.78	0.04	-0.37	-0.51
Total Other Income Expense Net	-0.53	-0.17	0.28	0.46	0.2	-0.06	-0.12	0.29	-0.14	0.2	0.15		0.14	0.51	0.24	-0.24	-0.01	0.25	0.09	-0.02	0.0	0.6	-0.65	-0.57
Net Income	-0.31	-0.58	-0.71	-0.59	-0.88	0.94	0.95	-0.74	0.95	-0.87	0.99	0.14		-0.43	-0.83	0.34	-0.78	0.85	-0.31	-0.16	-0.73	0.09	-0.31	-0.56
Income Tax Expense	0.1	0.45	0.49	0.58	0.46	-0.43	-0.48	0.28	-0.48	0.44	-0.35	0.51	-0.43		0.38	-0.44	0.6	-0.11	0.07	0.13	0.08	0.01	-0.69	0.15
Selling General Administrative	-0.05	0.44	0.92	0.85	0.99	-0.94	-0.91	0.97	-0.91	0.99	-0.86	0.24	-0.83	0.38		-0.44	0.67	-0.73	0.31	0.17	0.81	0.32	0.19	0.15
Cost Of Revenue	-0.18	-0.38	-0.42	-0.43	-0.46	0.47	0.38	-0.36	0.38	-0.46	0.35	-0.24	0.34	-0.44	-0.44		-0.48	-0.06	0.04	-0.32	-0.14	-0.12	0.27	-0.02
Selling And Marketing Expenses	0.41	0.92	0.73	0.68	0.78	-0.75	-0.76	0.48	-0.74	0.76	-0.75	-0.01	-0.78	0.6	0.67	-0.48		-0.58	0.34	0.2	0.58	-0.37	-0.09	0.69
Net Income From Continuing Ops	-0.26	-0.44	-0.62	-0.47	-0.74	0.76	0.82	-0.68	0.81	-0.74	0.86	0.25	0.85	-0.11	-0.73	-0.06	-0.58		-0.43	0.11	-0.77	0.1	-0.56	-0.55
Non Recurring	0.03	0.35	0.37	0.42	0.35	-0.26	-0.39	0.28	-0.39	0.35	-0.31	0.09	-0.31	0.07	0.31	0.04	0.34	-0.43		-0.16	0.51	-0.2	0.22	0.37
Non Operating Income Net Other	0.17	0.09	0.23	0.16	0.19	-0.17	-0.15	0.15	-0.14	0.19	-0.16	-0.02	-0.16	0.13	0.17	-0.32	0.2	0.11	-0.16		-0.16	0.06	0.02	0.01
Tax Provision	-0.04	0.48	0.67	0.61	0.81	-0.8	-0.78	0.78	-0.78	0.81	-0.78	0.0	-0.73	0.08	0.81	-0.14	0.58	-0.77	0.51	-0.16		0.07	0.38	0.32
Net Interest Income	-0.7	-0.62	0.18	0.26	0.19	-0.15	-0.08	0.5	-0.11	0.21	0.04	0.6	0.09	0.01	0.32	-0.12	-0.37	0.1	-0.2	0.06	0.07		-0.08	-0.87
Interest Income	0.14	-0.09	0.02	-0.17	0.15	-0.21	-0.22	0.25	-0.21	0.16	-0.37	-0.65	-0.31	-0.69	0.19	0.27	-0.09	-0.56	0.22	0.02	0.38	-0.08		0.27
Reconciled Depreciation	0.72	0.79	0.22	0.09	0.29	-0.33	-0.4	-0.03	-0.38	0.26	-0.51	-0.57	-0.56	0.15	0.15	-0.02	0.69	-0.55	0.37	0.01	0.32	-0.87	0.27

Click cells to compare fundamentals

Eyepoint Pharmaceuticals Account Relationship Matchups

Eyepoint Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.6M	2.6M	2.8M	2.4M	464K	440.8K
Interest Expense	6.2M	7.3M	5.5M	3.2M	1.2M	1.6M
Total Revenue	20.4M	34.4M	36.9M	41.4M	46.0M	48.3M
Gross Profit	17.7M	28.6M	28.8M	33.1M	41.4M	43.5M
Other Operating Expenses	68.2M	71.7M	92.2M	120.3M	121.1M	127.1M
Operating Income	(47.9M)	(37.3M)	(55.3M)	(78.9M)	(73.7M)	(70.0M)
Ebit	(47.0M)	(38.1M)	(52.9M)	(99.1M)	(69.5M)	(66.0M)
Research Development	15.4M	17.4M	28.5M	49.6M	64.7M	67.9M
Ebitda	(44.3M)	(35.5M)	(50.1M)	(96.6M)	(69.0M)	(65.6M)
Total Operating Expenses	65.5M	65.9M	84.0M	112.0M	116.5M	122.3M
Income Before Tax	(56.8M)	(45.4M)	(58.4M)	(102.3M)	(70.7M)	(67.2M)
Total Other Income Expense Net	(8.9M)	(8.1M)	(3.1M)	(2.6M)	3.0M	3.1M
Net Income	(63.0M)	(52.7M)	(63.9M)	(124.5M)	(70.8M)	(67.3M)
Income Tax Expense	6.2M	7.3M	5.5M	22.3M	83K	87.2K
Selling General Administrative	17.9M	20.7M	25.6M	34.8M	40.1M	42.1M
Cost Of Revenue	2.7M	5.8M	8.2M	8.3M	4.6M	4.4M
Selling And Marketing Expenses	29.8M	25.3M	27.5M	25.5M	11.7M	17.0M
Net Income Applicable To Common Shares	(56.8M)	(45.4M)	(58.4M)	(102.3M)	(92.0M)	(87.4M)
Net Income From Continuing Ops	(56.8M)	(45.4M)	(58.4M)	(102.3M)	(70.8M)	(67.3M)
Interest Income	1.1M	58K	292K	2.1M	6.9M	3.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eyepoint Historical Income Statement

About Eyepoint Income Statement Analysis

Eyepoint Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

Total Operating Expenses

Tax Provision

Eyepoint Pharmaceuticals income statement Correlations

Eyepoint Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eyepoint Pharmaceuticals income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Eyepoint Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Selling General Administrative	+ 0.99	Other Operating Expenses
Selling General Administrative	+ 0.99	Total Operating Expenses
Net Income	+ 0.99	Income Before Tax
Selling General Administrative	+ 0.97	Research Development

Total Operating Expenses	- 0.96	Operating Income
Operating Income	- 0.96	Other Operating Expenses
Total Operating Expenses	- 0.94	Ebitda
Selling General Administrative	- 0.94	Operating Income
Ebitda	- 0.94	Other Operating Expenses
Ebit	- 0.94	Other Operating Expenses